Influenza virus vaccination of patients with multiple sclerosis

Abstract

Prior to vaccination with a trivalent influenza vaccine (AT/Texas, AB/Beijing, and BP/Panama), sera from 19 MS patients had a significantly higher mean level of antibody than 9 normal subjects to AT strain of influenza, but not to AB or BP strains. After Flu vaccination, the mean anti-AT and anti-AB antibody titers significantly increased 4-fold in I I MS patients and 9 normal subjects. The ratio of MS responders (6II1), however, was lower than normal (8/9). The mean PBL proliferative response to the Flu antigens increased after vaccination significantly more in MS patients than in normal subjects, and increased in 9 of I I MS patients and 3 of 9 normal subjects. Although MS patients responded to Flu antigens with higher antibody levels and proliferative responses of PBL, than normal subjects, a clinical protective effect of the vaccine against Flu was not dearly demonstrated in these patients, and vaccination did not cause or protect against exacerbation of MS.

Keywords

multiple sclerosis influenza placebo peripheral blood lymphocytes Kurtzke Extended Disability Status Score

Get full access to this article

View all access options for this article.

References

Lee S. , Meiselas LE , Zingale SB , Richman R. (1960) Antibody production in Systemic lupus erytomatosus (LE) and rheumatoid arthritis. J Clin Invest 39: 1005.

Meiselas LE et al. (1961) Antibody production in rheumatic disease. The effect of brucella antigen. J Clin Invest 40: 1872 - 1881.

Ristow CS , Douglas G. , Condemi JJ (1978) Influenza Vaccination of Patients with Systemic Lupus Erythematosus. Annals of Internal Medicine 88: 786 - 789.

Louie JS et al. (1978) Clinical and Antibody Responses After Influenza Immunization in Systemic Lupus Erythematosus. Annals of Internal Medicine 88: 790 - 792.

Herron A. et al. (1979) Influenza Vaccination in Patients with Rheumatic Diseases. JAMA 6: 242.

Kepes JJ (1993) Large focal tumor-like demyelination lesion of the brain intermediate entity between multiple sclerosis and acute disseminated encephalomylitis? A study of 31 patients. Annals of neurology 33(1): 18 - 27.

de la Monte SM et al. (1986) Relapsing Central and Peripheral Demyelinating Diseases: Unusual Pathological Features. Arch Neurology 43: 626 - 629.

Pathak S. , Illavia SJ , Khalili-Shirazi A. , Webb HE ( 1990) Immunoelectron microscopical labeling of a glycolipid in the envelopes of brain cell-derived budding viruses, Semliki Forest, influenza and measles, using a monoclonal antibody directed chiefly against galactocerebroside resulting from Semliki Forest virus infection. J Neurol Sci 96: 293 - 302.

Shirazian D. et al. (1993) Presence of cross-reacting antibody to HTLV-1 and absence of antigens in patients with multiple sclerosis . J Lab Clin Med 122: 252 - 259.

10.

Mokhtarian F. , Swoveland P. (1987) Predisposition to EAE induction in resistant mice by prior infection with Semliki Forest virus. J Immunol 138: 3265 - 3268.

11.

Ghendon Y. (1990) The immune response to influenza vaccines. Acta Virologica 34(3): 295 - 304.

12.

Suss J. , Schmidt S. , Kretschmar M. , Wohanka N. (1991) The modulation of the specific and non-specific host response in case of influenza virus infection and vaccination in man . Experimental Pathology 41(3): 121-134.

13.

Nichel KL , Lind A. , Margolis KL et al. (1996) The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 333: 889 - 893.

14.

Aaron E Miller , Morgante LY , Buchwald SM et al. (1996) A multi-center, randomized, double-blind placebo-controlled trial of Influenza immunization in multiple sclerosis. Neurology in press.